CN1557352A - 菊苣水提取物的新用途 - Google Patents
菊苣水提取物的新用途 Download PDFInfo
- Publication number
- CN1557352A CN1557352A CNA2004100007863A CN200410000786A CN1557352A CN 1557352 A CN1557352 A CN 1557352A CN A2004100007863 A CNA2004100007863 A CN A2004100007863A CN 200410000786 A CN200410000786 A CN 200410000786A CN 1557352 A CN1557352 A CN 1557352A
- Authority
- CN
- China
- Prior art keywords
- group
- inulin
- hyperuricemia
- normal
- model
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000723343 Cichorium Species 0.000 title claims abstract description 22
- 235000007542 Cichorium intybus Nutrition 0.000 title claims abstract description 22
- 239000006286 aqueous extract Substances 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract description 68
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims abstract description 61
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims abstract description 61
- 229940116269 uric acid Drugs 0.000 claims abstract description 61
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 55
- 201000001431 Hyperuricemia Diseases 0.000 claims abstract description 39
- 210000004369 blood Anatomy 0.000 claims abstract description 31
- 239000008280 blood Substances 0.000 claims abstract description 31
- 235000005911 diet Nutrition 0.000 claims abstract description 14
- 230000037213 diet Effects 0.000 claims abstract description 13
- 208000006575 hypertriglyceridemia Diseases 0.000 claims abstract description 8
- 239000003112 inhibitor Substances 0.000 claims abstract description 3
- 108010092464 Urate Oxidase Proteins 0.000 claims abstract 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 144
- 229920001202 Inulin Polymers 0.000 claims description 132
- 229940029339 inulin Drugs 0.000 claims description 132
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 16
- 229940079593 drug Drugs 0.000 claims description 13
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 6
- 230000002503 metabolic effect Effects 0.000 claims description 5
- 206010003246 arthritis Diseases 0.000 claims description 4
- 230000036541 health Effects 0.000 claims description 4
- 239000003146 anticoagulant agent Substances 0.000 claims description 3
- 229940127219 anticoagulant drug Drugs 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 230000002961 anti-hyperuricemic effect Effects 0.000 claims 2
- 239000000463 material Substances 0.000 abstract description 2
- 206010058516 Hyperthrombinaemia Diseases 0.000 abstract 1
- 235000013402 health food Nutrition 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 description 53
- 230000037396 body weight Effects 0.000 description 29
- 241000699670 Mus sp. Species 0.000 description 21
- 241001465754 Metazoa Species 0.000 description 19
- 230000000694 effects Effects 0.000 description 19
- 102100033571 Tissue-type plasminogen activator Human genes 0.000 description 15
- 108050006955 Tissue-type plasminogen activator Proteins 0.000 description 15
- 210000002784 stomach Anatomy 0.000 description 15
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 14
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 14
- 210000002381 plasma Anatomy 0.000 description 14
- 108010093894 Xanthine oxidase Proteins 0.000 description 13
- 102100033220 Xanthine oxidase Human genes 0.000 description 13
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 13
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 9
- 229960002529 benzbromarone Drugs 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- 210000003743 erythrocyte Anatomy 0.000 description 9
- 230000000630 rising effect Effects 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 230000003203 everyday effect Effects 0.000 description 8
- 235000021590 normal diet Nutrition 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 230000003907 kidney function Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000002776 aggregation Effects 0.000 description 5
- 238000004220 aggregation Methods 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 235000020188 drinking water Nutrition 0.000 description 4
- 239000003651 drinking water Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000004062 sedimentation Methods 0.000 description 4
- 235000019786 weight gain Nutrition 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 244000184734 Pyrus japonica Species 0.000 description 3
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229940109239 creatinine Drugs 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000011552 rat model Methods 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 229940068041 phytic acid Drugs 0.000 description 2
- 235000002949 phytic acid Nutrition 0.000 description 2
- 239000000467 phytic acid Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- RYYCJUAHISIHTL-UHFFFAOYSA-N 5-azaorotic acid Chemical compound OC(=O)C1=NC(=O)NC(=O)N1 RYYCJUAHISIHTL-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 241000252983 Caecum Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 235000003228 Lactuca sativa Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229940123769 Xanthine oxidase inhibitor Drugs 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- ZFXVRMSLJDYJCH-UHFFFAOYSA-N calcium magnesium Chemical compound [Mg].[Ca] ZFXVRMSLJDYJCH-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- BJHIKXHVCXFQLS-UYFOZJQFSA-N fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 235000008085 high protein diet Nutrition 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000012613 in situ experiment Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229950000193 oteracil Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 201000005665 thrombophilia Diseases 0.000 description 1
- 230000003424 uricosuric effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000003064 xanthine oxidase inhibitor Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100007863A CN1323675C (zh) | 2004-01-19 | 2004-01-19 | 菊苣水提取物的新用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100007863A CN1323675C (zh) | 2004-01-19 | 2004-01-19 | 菊苣水提取物的新用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1557352A true CN1557352A (zh) | 2004-12-29 |
CN1323675C CN1323675C (zh) | 2007-07-04 |
Family
ID=34350507
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100007863A Expired - Lifetime CN1323675C (zh) | 2004-01-19 | 2004-01-19 | 菊苣水提取物的新用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1323675C (zh) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102028703B (zh) * | 2009-12-03 | 2013-07-31 | 张冰 | 菊粉的新用途 |
US20140302180A1 (en) * | 2011-11-18 | 2014-10-09 | Dialpha | Composition comprising chicory extract |
CN108404019A (zh) * | 2018-04-27 | 2018-08-17 | 韩世忠 | 复方菊苣根调节嘌呤代谢紊乱的固体制品及其制备方法 |
CN108634070A (zh) * | 2018-08-09 | 2018-10-12 | 民生药业集团有限公司 | 一种蕨菊茶及其制备方法 |
WO2020221184A1 (zh) * | 2019-04-28 | 2020-11-05 | 杭州泽健医药科技有限公司 | 一种具有降尿酸作用的药物组合物 |
WO2020221192A1 (zh) * | 2019-04-28 | 2020-11-05 | 杭州泽健医药科技有限公司 | 一种具有降尿酸和抗疲劳作用的药物组合物 |
WO2022021778A1 (zh) * | 2020-07-28 | 2022-02-03 | 深圳市老年医学研究所 | 防治高尿酸血症和痛风的药膳食疗组合物及其制备方法 |
CN115708851A (zh) * | 2022-10-20 | 2023-02-24 | 新疆华世丹药物研究有限责任公司 | 一种诃菊口服制剂及其制备方法和用途 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1061702A (zh) * | 1991-10-24 | 1992-06-10 | 淄博市营养保健食品研究所 | 菊苣系列疗效饮料的制法和用途 |
-
2004
- 2004-01-19 CN CNB2004100007863A patent/CN1323675C/zh not_active Expired - Lifetime
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102028703B (zh) * | 2009-12-03 | 2013-07-31 | 张冰 | 菊粉的新用途 |
US20140302180A1 (en) * | 2011-11-18 | 2014-10-09 | Dialpha | Composition comprising chicory extract |
CN108404019A (zh) * | 2018-04-27 | 2018-08-17 | 韩世忠 | 复方菊苣根调节嘌呤代谢紊乱的固体制品及其制备方法 |
CN108634070A (zh) * | 2018-08-09 | 2018-10-12 | 民生药业集团有限公司 | 一种蕨菊茶及其制备方法 |
WO2020221184A1 (zh) * | 2019-04-28 | 2020-11-05 | 杭州泽健医药科技有限公司 | 一种具有降尿酸作用的药物组合物 |
WO2020221192A1 (zh) * | 2019-04-28 | 2020-11-05 | 杭州泽健医药科技有限公司 | 一种具有降尿酸和抗疲劳作用的药物组合物 |
WO2022021778A1 (zh) * | 2020-07-28 | 2022-02-03 | 深圳市老年医学研究所 | 防治高尿酸血症和痛风的药膳食疗组合物及其制备方法 |
CN115708851A (zh) * | 2022-10-20 | 2023-02-24 | 新疆华世丹药物研究有限责任公司 | 一种诃菊口服制剂及其制备方法和用途 |
CN115708851B (zh) * | 2022-10-20 | 2023-11-21 | 新疆华世丹药物研究有限责任公司 | 一种诃菊口服制剂及其制备方法和用途 |
Also Published As
Publication number | Publication date |
---|---|
CN1323675C (zh) | 2007-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1814601A (zh) | 具有免疫抑制作用的青蒿素衍生物及药物组合物 | |
CN1245198C (zh) | 一种治疗糖尿病的中药组合物及其制备方法 | |
CN1557352A (zh) | 菊苣水提取物的新用途 | |
CN101062084A (zh) | 一种抗肝炎的药物组合物 | |
CN1559519A (zh) | 一种夏枯草提取物及其制备方法与用途 | |
CN1895263A (zh) | 牛磺酸在制备含有葛根素的注射剂中的应用 | |
CN100341492C (zh) | 一种参芪降糖软胶囊及其制备检测方法 | |
CN1201805C (zh) | 一种用于放化疗减毒增效的药物组合物及其制备方法 | |
CN1294936C (zh) | 一种治疗糖尿病的药物及其制备方法 | |
CN1112439A (zh) | 治疗糖尿病的中药及其生产方法 | |
CN1491719A (zh) | 蝉花在制备治疗慢性肾功能衰竭的药物中的应用 | |
CN1565530A (zh) | 一种治疗尿失禁的药物及其制备方法 | |
CN1733116A (zh) | 治疗高血压症的药物制剂及其制备方法 | |
CN1813822A (zh) | 一种用于制备糖尿病治疗药物的天然药物组合物 | |
CN1631895A (zh) | 苦杏仁苷的制备方法和苦杏仁苷在制备促进心脑胰及伤口血液循环的苦杏仁苷制剂中的应用 | |
CN1294925C (zh) | 一种治疗高血压和高血脂的中药及其制备方法 | |
CN1197563C (zh) | 一种用于治疗男性不育的复方组合物 | |
CN100341490C (zh) | 一种参芪降糖分散片及其制备检测方法 | |
CN1513448A (zh) | 藤黄酸及藤黄酸复合物的药物组合物制剂 | |
CN1483327A (zh) | 含有二氢杨梅素和杨梅素的组合物的保健食品 | |
CN1238038C (zh) | 一种补肾健脾填精补髓的药物及其制备方法 | |
CN1586604A (zh) | 一种莪术注射制剂及其制备方法 | |
CN1853654A (zh) | 一种含有珍珠和维生素的口服制剂 | |
CN1709439A (zh) | 一种参芪降糖滴丸及其制备检测方法 | |
CN1239197C (zh) | 治疗中风的药物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ASS | Succession or assignment of patent right |
Owner name: ZHANG BING Free format text: FORMER OWNER: BEIJING CHINESE MEDICINE COLLEGE Effective date: 20041105 |
|
C06 | Publication | ||
C41 | Transfer of patent application or patent right or utility model | ||
PB01 | Publication | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20041105 Address after: 100102 School of traditional Chinese medicine, Beijing University of Chinese Medicine, 6 South Central Road, Chaoyang District, Beijing, Wangjing Applicant after: Zhang Bing Address before: Box 11, 158 East Third Ring Road, Beijing, North China Applicant before: Beijing University of Chinese Medicine |
|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200107 Address after: 100029, No. 11 East Third Ring Road, Chaoyang District, Beijing Patentee after: Beijing University of Chinese Medicine Address before: 100102 School of traditional Chinese medicine, Beijing University of Chinese Medicine, 6 South Central Road, Chaoyang District, Beijing, Wangjing Patentee before: Zhang Bing |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20041229 Assignee: Zhiqi Pharmaceutical (Beijing) Co.,Ltd. Assignor: BEIJING University OF CHINESE MEDICINE Contract record no.: X2020980007649 Denomination of invention: New uses of chicory water extract Granted publication date: 20070704 License type: Exclusive License Record date: 20201109 |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20070704 |